ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL

2021 ◽  
Vol 37 (10) ◽  
pp. S62-S63
Author(s):  
A Sharma ◽  
S Inzucchi ◽  
J Testani ◽  
A Ofstad ◽  
D Fitchett ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Outcomes ◽  
Outcome Trial

1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1144-P
Author(s):  
ABHINAV SHARMA ◽  
ANNE PERNILLE OFSTAD ◽  
TARIQ AHMAD ◽  
BERNARD ZINMAN ◽  
ISABELLA ZWIENER ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Sglt2 Inhibition ◽  
Outcome Trial

Efficacy and Cardiovascular Safety of Meglitinides

2020 ◽  
Vol 15 ◽  
Author(s):  
Jim Philip ◽  
Cornelius James Fernandez
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Outcomes ◽  
Individual Therapy ◽  
Hypoglycemic Agents ◽  
Current Evidence ◽  
Minimal Risk ◽  
Cardiovascular Safety

: Meglitinides are a group of oral hypoglycemic medications currently approved for the treatment of type 2 diabetes mellitus (T2DM). Two meglitinide molecules, Repaglinide and Nateglinide,are presently in use. Repaglinide is preferred because of its superior glycemic efficacy.They have modest efficacy with a mean decrement of glycosylated haemoglobin (HbA1c) ranging between -0.2 to -1.50% with individual therapy. Additional HbA1c reduction can occur with combination therapy with other oral hypoglycemics. This class of drugs is effective in controlling postprandial hyperglycemia with minimal risk of hypoglycemia.It is also useful in patients in with variable meal timings, especially in the elderly, and in patients with renal failure. There are is a dearth of long-term studies on meglitinides to assess cardiovascular outcomes or mortality in T2DM,although the Nateglinide and Valsartan in Impaired Glucose ToleranceOutcomes Research (NAVIGATOR) study showed no difference between Nateglinide and placebo with regard to the core composite cardiovascular outcomes. Based on a PubMed literature search using key words: ‘meglitinides’, ‘repaglinide’, ‘nateglinide’, ‘HbA1c’, ‘glycated haemoglobin’, ‘cardiovascular safety’, ‘cardiovascular events’, ‘cardiovascular outcome trials’, ‘type 2 diabetes mellitus’ and heart failure, and combining the search terms using Boolean operators ‘AND’, ‘OR’ and ‘NOT’ as needed we compiled current evidence for use of these oral hypoglycemic agents in clinical use. This article is an attempt to review the efficacy and cardiovascular (CV) safety of Meglitinides to help clinicians to use this class of oral hypoglycaemic agents prudently.

scholarly journals Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

2013 ◽  
Vol 369 (14) ◽  
pp. 1317-1326 ◽  
Author(s):  
Benjamin M. Scirica ◽  
Deepak L. Bhatt ◽  
Eugene Braunwald ◽  
P. Gabriel Steg ◽  
Jaime Davidson ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Outcomes
Sign in / Sign up

Export Citation Format

Share Document